Combined Evaluation of AFP, CA15-3, CA125, CA19-9, and CEA Tumor Markers in Patients with Hepatitis B and C
Background: This study aimed to determine the role of tumor markers AFP, CA15-3, CA125, CA19-9 and CEA in patients with hepatitis B and C.
Methods: This descriptive cross-sectional study was performed from Oct 2012 to Oct 2014. Serum samples of 129 patients with hepatitis B and C referred to Guilan Liver and Digestive Disease Research Center in Rasht, Iran were collected and checked for the existence of the listed tumor markers by ELISA.
Results: No increase in serum levels of tumor marker CA19-9, CEA and CA15-3 were seen in patients with hepatitis (P>0.05). In patients with hepatitis B, increase in CA125 were observed (P=0.03). In hepatitis C patients, there was an increase in AFP levels (P=0.03).
Conclusion: The levels of AFP and CA125 markers were high in hepatitis C and hepatitis B, respectively. However, the increased levels were not seen is malignancy. Due to the small sample size, further study is necessary to find the reasons of the increase.
Dennis LK, Eugene Stephen H, Dan L,J Larry J, Anthony SF (2004). Harrison's principles of internal medicine. 16 th ed. Mc Graw- Hill. New York, pp. 1855-60.
Cohan N, Zandieh T, Samiei SH, Ataie Z, Kavari M (2006). The prevalence and clinical significance Hepatitis B and C co-infection. Iran J Med Sci, 31(3):156-159.
Lok As, McMahon BJ (2001). Chron-ic hepatitis B: update of recommenda-tions. Hepatology, 34(6):1225-41.
Massarat MS, Tahaghoghi mehrizi S (2002). Iranian national health survey: a brief report. Arch Iran Med, 5(2):73-79.
Alavian SM, Fallahian F, Bagheri lankarani K (2007). The changing epidemiology of viral Hepatitis Bin Iran. 16(4): 403-6. J Gastrointestin Liver Dis16 (4):403-6.
Pour shams A, Nasiri J, Mohammad khani A, Nasrollahzadeh D (2004). Hepatitis B in Gonbad- kavvos: prevalence, risk factors and interfamilial spreading. Govaresh, Iran Hepatol, 4(9): 222-5.
HosseiniASl, Avijgan M, Mohammad nejhad M (2004). High prevalence of HBV, HCV, HIV infection gypsy population residing in Shahr-e- kord. Aerch Iran Med, 7(1): 20-22.
Zali MR, Mohammad K, farhadi Ad, Masjedi MR, zargar A, Nawroozi A (1996). Epidemiology of hepatitis B in the Islamic Republic of Iran. East Mediterr Health J, 2(2): 290-8.
Johnson RJ, Couser WG (1990). Hepatitis B infection and renal diseases: clinical, immunopathogenetic and therapeutic considerations. Kidney Int, 37: 663.
Jihadi AA, Avijgan M, Hafizi M (2006). Prevalence of HBV and HCV infections and associated risk factors in addict prisoners. Iran J Public Health, 35:33-6.
Shi J, Su Q, Zhang G, Huang G, Zhu Y (2010). An intelligent decision support algoritm for diagnosis of colorectal cancer through serum tumor markers. Comput Methods Programs Biomed , 100: 97-107.
Gadducci A, tana R, Cosio S, Genazzani AR (2008). The serum assay of tumor markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer. Crit Rev Oncol Hematol, 66:10-20.
Motoo Y, Satomura Y, Mouri I (1999). Serum levels of pancreatitis-associated protein in digestive diseases with special reference to gastrointestinal cancers. Dig Dis Sci, 44:1142-47.
Maestranzi S, Przemioslo R, Mitchel H (1998). The effect of benign and malignant liver disease on the tumor markers CA19-9 and CEA. Ann Clin Biochem, 35:99-103.
Boehm MK, Perkins SJ (2000). Structural models for carcino embryonic antigen and its complex with the single-chain antibody molecule. M4E230. Febs Letters, 475:11-16.
Heydarpour M, Tavakkoli H, Shafiei D, Koleini N, Arjmandpour A (2011). Correlation between the Level of the Tumor Markers with the Stage of Liver Fibrosis in Patients with Chronic Hepatitis and Cirrhosis. J Isfahan Med School, 29 (155):1239-46.
Matievskay NV, Syczewska MW, Tsyrkunov VM, Boron-kaczmarsk A (2003). Serum alpha-fetoprotein (AFP) levels in patients with chronic HBV and HCV infections. Gastroenterol Pol, 10:35-40.
Di Bisceglie AM, Sterling RK, Chung RT, et al (2005). Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the -C trail. J Hepatol, 43:434-41.
Bruden Dl, McMahon BJ, Hennessy TW (2004). Estimating the date of hepatitis C virus infection from patients’ interviews and antibody tests on stored sera. Am J Gastroenterol, 99:1517-22.
Tai WC, Hu TH, Wang JH (2009).Clinical implications of alpha-fetoprotein in chronic hepatitis C. J Formos Med Assoc, 108 :210-18.
Yu ML, Chuang WL, Chen SC (2001). Changing prevalence of hepatitis C virus genotype: molecular epidemiology and clinical implications in tertiary referral center in Taiwan. J Med Virol, 65:58-65.
Bertino G, Ardiri AM, Boemi P (2007). Meaning of elevated CA19-9 serum levels in chronic hepatitis and HCV-related cirrhosis. Minerva Gastroenterol Dietol, 53:305-9.
George PK, Lowenstein MS, Brien MJ et al (1982). Circulating CEA levels in patients with fulminant hepatitis. Dig Dis Sci, 27: 139-142.
Al-boki EL-H, Abd M, Shade M, et al(2011). Do serum CA19-9 and CA125 levels predict the severity of HCV-related liver fibrosis? Egyption Liver J, 1(1): 33-7.
Derarbhavi H, Kaese D, William AW (2002). Cancer antigen 125 in patients with chronic liver diseases. Mayo Clin Proc, 77: 538-41.
Canney PA, Moore M, Wilkinson PM (1984). Ovarian cancer antigen CA125: A prospective clinical assessment of its role as a tumor marker. Br J Cancer, 50: 765-9.
Molina R, Filella X, Bruix J (1991). Cancer antigen 125 in serum and ascetic fluid of patients with liver diseases. Clin Chem, 37:1379-83.
Kobeisy M, Morsy KH, Galal M, Sayed S, Ashamwy M, Mohamad F (2012). Clinical significance of elevated alpha-fetoprotein (AFP) in patients with chronic hepatitis C without hepatocellular carcinoma in Upper Egypt. Arab J Gastroenterol, 13: 49-53.
Schöniger-Hekele M, Muler C (2006). The combined elevation of tumor marker CA19-9 and CA125 in liver disease patients is highly specific for severe liver fibrosis. Dig Dis Sci, 51; 338-45.
|Issue||Vol 45 No 12 (2016)|
|Tumor markers Hepatitis B Hepatitis C ELISA|
|Rights and permissions|
|This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.|